Cell & Gene Therapy Manufacturing Services Market

Thermo Fisher Scientific (US) and Merck KGaA (Germany) are the Key Players in the Cell & Gene Therapy Manufacturing Services Market

The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7 billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs. However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of this market to a certain extent.

The global cell & gene therapy manufacturing services market is highly consolidated. Key players in the PDX models market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Charles River Laboratories (US), Lonza (Switzerland), Catalent (US), WuXi AppTec (China), Takara Bio Inc. (Japan), Nikon Corporation (Japan), FUJIFILM Holdings Corporation (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), Oxford Biomedica plc (UK), and Cell and Gene Therapy Catapult (UK). Partnerships, agreements, and collaborations are the key growth strategies undertaken by these companies to maintain their positions in the market.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific (US):  Thermo Fisher was the leading player in the cell & gene therapy manufacturing services market in 2020. The company has a strong geographic footprint serving over 400,000 customers in pharmaceutical and biotech companies. The large share of Thermo Fisher in this market can be attributed to its broad product portfolio, vast experience, and vast distribution channel. Thermo Fisher also strengthened its presence in the market through acquisitions. For instance, in 2019, Thermo Fisher Scientific acquired Brammer Bio, a company engaged in viral vector manufacturing for gene and cell therapies, for USD 1.7 billion. The company’s distribution network comprises a broad sales force and a global network of resellers and distributors. Its extensive R&D activities enable it to increase its depth of capabilities in technologies, software, and services. The company invested USD 1,182 million in R&D activities in 2020, representing a growth of 18% compared to 2019 (it invested USD 1,003 million in R&D in 2019).

Merck KGaA (Germany): Merck provides a wide range of products as well as services in the market. Geographically, the company has its footprint in 65 countries across the globe and is further expanding its network. For instance, in 2020, the company opened its largest M Lab Collaboration Center in Shanghai (China) to provide its drug development services to the growing pharmaceutical industry in Asia. It also benefits from its strong R&D capabilities. In 2020, it invested USD 2.61 billion in R&D, which was 13% of its revenue. The company strengthened its position in the cell & gene therapy manufacturing services market through geographical expansions. In March 2021, Merck announced an investment of USD 30.4 million for setting up a single-use assembly production unit at its Life Science Center in France. With this expansion, the company will increase its capacity for the production of lifesaving therapies. The company’s strong geographic presence, distribution network, and innovative products would help it to maintain its position in the cell & gene therapy manufacturing services market in the coming years.

Charles River Laboratories (US): Charles River offers services for basic research, discovery, safety and efficacy, clinical support, and manufacturing to pharmaceutical, biotechnology, agrochemical, government, and academic organizations around the world. The company’s growth in the cell & gene therapy manufacturing services market can be attributed to its wide geographical presence. It operates multiple production centers, including barrier rooms and isolator facilities, in three continents—North America, Europe, and Asia. The company follows inorganic strategies such as agreements, acquisitions, and collaborations to strengthen its presence in the cell & gene therapy manufacturing services market. In 2021, the company acquired Cognate BioServices to increase its cell & gene therapy manufacturing capabilities.

Related Reports:

Cell & Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication (Cancer, Orthopedic), Application (Clinical, Commercial), End User (Pharma & Biotech, Academia) - Global Forecast to 2026

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Report Code
BT 7944
RI Published ON
Choose License Type
Request Customization
Speak to Analyst
Speak to Analyst
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
  • What are the Known and Unknown Adjacencies Impacting the Cell & Gene Therapy Manufacturing Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
©2021 MarketsandMarkets Research Private Ltd. All rights reserved